ALBUQUERQUE, N.M., Oct. 15 /PRNewswire-FirstCall/ -- Two clinical research scientists this month joined Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, to assist with commercialization efforts of the company's early lung cancer detection testing and other cancer diagnostic technology.
"Constance Dorian brings strong analytical skills and significant understanding of diagnostic products development and FDA regulations to Biomoda. She will be an important asset in all our clinical studies," said John Cousins, President of Biomoda. "I'm equally pleased to have Brett Roden on our team. He is highly skilled in research and production science with a solid background in pharmacological and biomolecular engineering."
Before joining Biomoda, Ms. Dorian worked as a research scientist in clinical studies of fluorescence spectroscopy to noninvasively measure diabetes. She managed Technical Operations for several California biomedical firms that manufactured diagnostic products and commercial controls for the clinical and hospital laboratory markets, developed and tested in vitro diagnostic products and developed new drugs in the treatment of thrombosis. Mr. Roden formerly worked as a research assistant in the clinical studies of multiple assays, including in vivo microdialysis, cell isolation, tissue preparation, radioligand binding assays and protein quantification.
Biomoda's technology is based on a patented porphyrin application that
preferentially binds to cancerous or aberrant cells extracted from lung
sputum samples. Cancerous cells glow red under fluorescent light to allow
detection under a microscope. The patented technology, a non-invasive
cytology based assay, is designed for cancer screening of large populations
at a reasonable cost. Current diagnostic methods for lung cancer, including
CT scans and X-rays, often detect the disease only at more advanced s
'/>"/>
| SOURCE Biomoda, Inc. Copyright©2007 PR Newswire. All rights reserved |